RBC Capital Markets is standing by its bullish view on Waters Corporation, even as the lab-equipment maker's latest quarterly guidance comes in lighter than some investors hoped. In a research note published Monday, the bank called Waters' fourth-quarter outlook "conservative" and said the company's long-term growth story—targeting high single-digit revenue growth by 2027—remains intact.
The optimism comes with a caveat: RBC trimmed its 2027 margin assumptions for Waters, citing the drag from the recently acquired Becton Dickinson (BD) businesses. Those units, which Waters bought as part of a deal to expand its portfolio, are expected to grow only modestly in the near term, making the combined company's financials look less punchy over the next few quarters.
What's behind the conservative guidance?
Waters, a maker of analytical instruments and software used in laboratories, has been navigating a mixed demand environment. While its core business—serving pharmaceutical, biotech, and academic customers—has shown resilience, management appears to be taking a cautious approach to near-term guidance.
RBC said it doesn't see an obvious reason for Waters' core business to slow down. However, the bank also noted that management has limited incentive to raise guidance right now. That's partly because the acquired BD businesses are viewed as roughly low-growth, which could weigh on the combined company's performance in the coming quarters.
For everyday investors, this means the stock's near-term moves may be driven more by expectations than by actual results. If Waters beats its conservative guidance, the market could react positively. But if the BD integration proves bumpy, there's room for disappointment.
The BD acquisition: a double-edged sword
Waters' acquisition of Becton Dickinson's biosciences and diagnostics businesses was a strategic move to broaden its product offerings and customer base. But integrating new businesses always carries risks, and RBC's trimmed margin assumptions reflect that reality.
BD's businesses are not expected to grow as fast as Waters' core operations, which means they could dilute overall growth and profitability in the short term. That's a common pattern in M&A: the acquired assets often take time to reach their full potential, and until then, they can drag on the parent company's financials.
RBC's view is that this drag is temporary. The bank still sees Waters reaching high single-digit growth by 2027, suggesting that the long-term benefits of the deal will eventually outweigh the near-term costs.
What it means for investors
For investors, the key takeaway is that RBC sees the glass as half full. The conservative guidance could set up a beat-and-raise scenario, where Waters exceeds its own expectations and lifts its outlook later. That's often a positive catalyst for a stock.
But there's also a risk that the BD businesses underperform for longer than expected, putting pressure on margins and delaying the growth story. Investors should watch for signs of integration progress in upcoming earnings calls.
RBC's stance is consistent with its broader view on companies with strong core franchises. For example, the bank has recently highlighted growth opportunities at Jersey Mike's and potential beats at Marvell, showing a pattern of identifying companies where conservative guidance may be masking underlying strength.
In the case of Waters, the market will likely focus on whether the company can deliver on its 2027 targets. If it does, the current valuation could look attractive. If not, the stock could face headwinds.
The broader context
Waters operates in the life sciences tools sector, which has seen mixed demand as biotech funding fluctuates and academic budgets tighten. However, the long-term trend toward precision medicine and advanced analytics supports steady growth for companies like Waters.
RBC's note also comes amid a broader market environment where investors are paying close attention to guidance and margin trends. With interest rates still elevated, companies that can grow efficiently are often rewarded, while those that disappoint on margins can be punished.
For now, RBC is betting that Waters' core strength will shine through, even as the BD integration creates some noise. The bank's decision to trim margin assumptions but maintain the growth outlook suggests it sees the 2027 story as still very much alive.
Investors should keep an eye on Waters' next earnings report for clues about how the BD businesses are performing and whether management's conservative guidance was warranted. As always, past performance is no guarantee of future results, and individual circumstances vary.
